Quick Answer
Cogent Biosciences, Inc. reported Diluted EPS of $2.16 per share (loss) for fiscal year 2025.
Cogent Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.16 | -11.3% |
| 2024 | -$1.94 | +0.0% |
| 2023 | -$1.94 | -12.1% |
| 2022 | -$1.73 | +7.5% |
| 2021 | -$1.87 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.50 | +3.8% | +5.7% |
| June 30, 2025 | -$0.53 | -23.3% | -1.9% |
| March 31, 2025 | -$0.52 | -6.1% | +0.0% |
| September 30, 2024 | -$0.52 | +18.8% | -20.9% |
| June 30, 2024 | -$0.43 | +27.1% | +12.2% |
| March 31, 2024 | -$0.49 | +10.9% | +23.4% |
| September 30, 2023 | -$0.64 | -28.0% | -8.5% |
| June 30, 2023 | -$0.59 | +16.9% | -7.3% |
- Cogent Biosciences, Inc. showed a decrease of -11.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Cogent Biosciences, Inc.’s diluted eps has declined by 15.5% (from $1.87 per share (loss) to $2.16 per share (loss)).
- The most recent figure is from Cogent Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: